Table 1 Baseline demographics of patients in the metformin and insulin group
Metformin (58) | Met+ Ins (32) | Insulin (17) | |
|---|---|---|---|
Average age in years (range) | 32 (22–42) | 34 (25–45) | 34 (20–46) |
20–40 | 56 (96.6%) | 28 (87.5%) | 14 (82.4%) |
41+ | 2 (3.4%) | 4 (12.5%) | 3 (17.6%) |
Average parity (range) | 2 (0–9) | 2 (0–5) | 2 (0–6) |
Nulliparity | 13 (22.4%) | 2 (6.3%) | 5 (29.4%) |
1–4 | 42 (72.4%) | 29 (90.6%) | 11 (64.7%) |
5+ | 3 (5.2%) | 1 (3.1%) | 1 (5.9%) |
Ethnicity | |||
Middle Eastern | 3 (5.2%) | 6 (18.7%) | 7 (41.2%) |
Rest of Asia | 45 (77.6%) | 19 (59.4%) | 6 (35.3%) |
Africa | 10 (17.2%) | 7 (21.9%) | 4 (23.5%) |
Average BMI in kg/m2 (range) | 30 (23–41) | 32 (23–52) | 35 (23–53) |
18.5–24.9 | 4 (6.9%) | 2 (6.3%) | 1 (5.9%) |
25–29.9 | 22 (37.9%) | 12 (37.5%) | 2 (11.7%) |
30–34.9 | 26 (44.8%) | 7 (21.9%) | 6 (35.3%) |
> 35 | 6 (10.4%) | 11 (34.3%) | 8 (47.1%) |